Literature DB >> 28007909

Mendelian randomization estimates of alanine aminotransferase with cardiovascular disease: Guangzhou Biobank Cohort study.

Lin Xu1, Chao Qiang Jiang2, Tai Hing Lam1,3, Wei Sen Zhang2, Feng Zhu2, Ya Li Jin2, G Neil Thomas4, Kar Keung Cheng4, C Mary Schooling1,5.   

Abstract

Observational studies of the association of alanine aminotransferase (ALT) levels with ischaemic heart disease (IHD) and cardiovascular disease (CVD) risk factors are inconsistent, probably because of confounding and reverse causality. Mendelian randomization (MR) provides less confounded results. We used MR analysis to assess the associations of ALT (U/L) with IHD, diabetes and other CVD risk factors. We used instrumental variable analysis based on two single nucleotide polymorphism (SNPs) HSD17B13/MAPK10 (rs6834314) and PNPLA3/SAMM50 (rs738409) to assess the associations of ALT (U/L) with IHD, diabetes and other CVD risk factors in the Guangzhou Biobank Cohort Study (GBCS). Observationally in 19,925 participants ALT levels were strongly positively associated with self-reported IHD, systolic and diastolic blood pressure, low-density lipoprotein- and total cholesterol, triglycerides, fasting glucose, body mass index, waist circumference, heart rate (HR) and diabetes, but were not associated with uncorrected QT interval, HR-corrected QT interval or high-density lipoprotein-cholesterol. In the MR study, using a credible genetic instrument (F-statistic = 23) for ALT, ALT levels were negatively associated with IHD (odds ratio (OR) 0.92, 95% confidence interval (CI) 0.87 to 0.97) and triglycerides (β - 0.08, 95% CI - 0.13 to - 0.03), but were not associated with other CVD risk factors. Our results using Mendelian randomization suggest that ALT reduces the risk of IHD, probably through reducing triglyceride levels. The underlying mechanisms deserve further investigation.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28007909     DOI: 10.1093/hmg/ddw396

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  12 in total

1.  Mendelian randomization for investigating causal roles of biomarkers in multifactorial health outcomes: a lesson from studies on liver biomarkers.

Authors:  Ali Abbasi
Journal:  Int J Epidemiol       Date:  2017-10-01       Impact factor: 7.196

2.  17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.

Authors:  Yanling Ma; Olga V Belyaeva; Philip M Brown; Koji Fujita; Katherine Valles; Suman Karki; Ynto S de Boer; Christopher Koh; Yanhua Chen; Xiaomeng Du; Samuel K Handelman; Vincent Chen; Elizabeth K Speliotes; Cara Nestlerode; Emmanuel Thomas; David E Kleiner; Joseph M Zmuda; Arun J Sanyal; Natalia Y Kedishvili; T Jake Liang; Yaron Rotman
Journal:  Hepatology       Date:  2019-03-05       Impact factor: 17.425

3.  Liver Function and Risk of Type 2 Diabetes: Bidirectional Mendelian Randomization Study.

Authors:  N Maneka G De Silva; Maria Carolina Borges; Aroon D Hingorani; Jorgen Engmann; Tina Shah; Xiaoshuai Zhang; Jian'an Luan; Claudia Langenberg; Andrew Wong; Diana Kuh; John C Chambers; Weihua Zhang; Marjo-Ritta Jarvelin; Sylvain Sebert; Juha Auvinen; Tom R Gaunt; Deborah A Lawlor
Journal:  Diabetes       Date:  2019-05-14       Impact factor: 9.461

Review 4.  Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.

Authors:  Mohammed Eslam; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-10-22       Impact factor: 46.802

5.  The association between serum alanine aminotransferase and hypertension: A national based cross-sectional analysis among over 21 million Chinese adults.

Authors:  Jiajing Jia; Ying Yang; Fangchao Liu; Minjin Zhang; Qin Xu; Tonglei Guo; Long Wang; Zuoqi Peng; Yuan He; Yuanyuan Wang; Ya Zhang; Hongguang Zhang; Haiping Shen; Yiping Zhang; Donghai Yan; Xu Ma; Puhong Zhang
Journal:  BMC Cardiovasc Disord       Date:  2021-03-19       Impact factor: 2.298

6.  Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events.

Authors:  Sabrina Rüschenbaum; Katharina Schwarzkopf; Mireen Friedrich-Rust; Florian Seeger; Fabian Schoelzel; Yolanda Martinez; Stefan Zeuzem; Jörg Bojunga; Christian M Lange
Journal:  Hepatol Commun       Date:  2018-06-06

7.  The effect of liver enzymes on adiposity: a Mendelian randomization study.

Authors:  Junxi Liu; Shiu Lun Au Yeung; Man Ki Kwok; June Yue Yan Leung; Shi Lin Lin; Lai Ling Hui; Gabriel Matthew Leung; C Mary Schooling
Journal:  Sci Rep       Date:  2019-11-14       Impact factor: 4.379

8.  The eMERGE genotype set of 83,717 subjects imputed to ~40 million variants genome wide and association with the herpes zoster medical record phenotype.

Authors:  Ian B Stanaway; Taryn O Hall; Elisabeth A Rosenthal; Melody Palmer; Vivek Naranbhai; Rachel Knevel; Bahram Namjou-Khales; Robert J Carroll; Krzysztof Kiryluk; Adam S Gordon; Jodell Linder; Kayla Marie Howell; Brandy M Mapes; Frederick T J Lin; Yoonjung Yoonie Joo; M Geoffrey Hayes; Ali G Gharavi; Sarah A Pendergrass; Marylyn D Ritchie; Mariza de Andrade; Damien C Croteau-Chonka; Soumya Raychaudhuri; Scott T Weiss; Matt Lebo; Sami S Amr; David Carrell; Eric B Larson; Christopher G Chute; Laura Jarmila Rasmussen-Torvik; Megan J Roy-Puckelwartz; Patrick Sleiman; Hakon Hakonarson; Rongling Li; Elizabeth W Karlson; Josh F Peterson; Iftikhar J Kullo; Rex Chisholm; Joshua Charles Denny; Gail P Jarvik; David R Crosslin
Journal:  Genet Epidemiol       Date:  2018-10-08       Impact factor: 2.135

Review 9.  Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?

Authors:  Karthik Chandrasekharan; William Alazawi
Journal:  Front Pharmacol       Date:  2020-01-08       Impact factor: 5.810

Review 10.  Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target.

Authors:  Takashi Motomura; Sriram Amirneni; Ricardo Diaz-Aragon; Lanuza A P Faccioli; Michelle R Malizio; Michael C Coard; Zehra N Kocas-Kilicarslan; Carla Frau; Nils Haep; Alina Ostrowska; Rodrigo M Florentino; Alejandro Soto-Gutierrez
Journal:  J Pers Med       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.